Clinical trial data shows preserved beta-cell function key to new paradigms in diabetes care

Simi Ahmed, Ph.D., Executive Director, C-PathThe opportunity now is to collaboratively build shared regulatory-science approaches that define and quantify the clinical relevance of preserved beta-cell function in relation to how a person feels, functions or survives. By bringing together regulators, academia, patient organizations and drug developers in a neutral, precompetitive environment, C-Path remains committed to strengthening the infrastructure needed to accelerate therapeutic innovation across multiple stages of type 1 diabetes."

Addressing these questions will require sustained alignment around regulatory expectations and evidence-generation strategies across the entire T1D drug development ecosystem. Through its neutral, precompetitive model, C-Path helps the field tackle foundational scientific and regulatory challenges that no single organization can efficiently address alone.

Source:

Critical Path Institute (C-Path)